Apo-AI/AII peptide derivatives

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S002600, C514S013800, C530S324000, C530S325000, C530S326000, C530S344000, C530S350000, C435S069100, C435S069700, C930S010000, C930S030000

Reexamination Certificate

active

06743778

ABSTRACT:

BACKGROUND OF THE INVENTION
A need exists for recombinant or modified therapeutic agents having Apo-AI amphipathic helix peptide activity.
Recombinant and modified proteins are an emerging class of therapeutic agents. Useful modifications of protein therapeutic agents include combination with the “Fc” domain of an antibody and linkage to polymers such as polyethylene glycol (PEG) and dextran. Such modifications are discussed in detail in a patent application entitled, “Modified Peptides as Therapeutic Agents,” U.S. Ser. No. 09/428,082, PCT appl. no. WO 99/25044, which is hereby incorporated by reference in its entirety.
A much different approach to development of therapeutic agents is peptide library screening. The interaction of a protein ligand with its receptor often takes place at a relatively large interface. However, as demonstrated for human growth hormone and its receptor, only a few key residues at the interface contribute to most of the binding energy. Clackson et al. (1995),
Science
267: 383-6. The bulk of the protein ligand merely displays the binding epitopes in the right topology or serves functions unrelated to binding. Thus, molecules of only “peptide” length (2 to 40 amino acids) can bind to the receptor protein of a given large protein ligand. Such peptides may mimic the bioactivity of the large protein ligand (“peptide agonists”) or, through competitive binding, inhibit the bioactivity of the large protein ligand (“peptide antagonists”).
Phage display peptide libraries have emerged as a powerful method in identifying such peptide agonists and antagonists. See, for example, Scott et al. (1990),
Science
249: 386; Devlin et al. (1990),
Science
249: 404; U.S. Pat. Nos. 5,223,409, issued Jun. 29, 1993; 5,733,731, issued Mar. 31, 1998; 5,498,530, issued Mar. 12, 1996; 5,432,018, issued Jul. 11, 1995; 5,338,665, issued Aug. 16, 1994; 5,922,545, issued Jul. 13, 1999; WO 96/40987, published Dec. 19, 1996; and WO 98/15833, published Apr. 16, 1998 (each of which is incorporated by reference in its entirety). In such libraries, random peptide sequences are displayed by fusion with coat proteins of filamentous phage. Typically, the displayed peptides are affinity-eluted against an antibody-immobilized extracellular domain of a receptor. The retained phages may be enriched by successive rounds of affinity purification and repropagation. The best binding peptides may be sequenced to identify key residues within one or more structurally related families of peptides. See, e.g., Cwirla et al. (1997),
Science
276: 1696-9, in which two distinct families were identified. The peptide sequences may also suggest which residues may be safely replaced by alanine scanning or by mutagenesis at the DNA level. Mutagenesis libraries may be created and screened to further optimize the sequence of the best binders. Lowman (1997),
Ann. Rev. Biophys. Biomol. Struct.
26: 401-24.
Structural analysis of protein—protein interaction may also be used to suggest peptides that mimic the binding activity of large protein ligands. In such an analysis, the crystal structure may suggest the identity and relative orientation of critical residues of the large protein ligand, from which a peptide may be designed. See, e.g., Takasaki et al. (1997),
Nature Biotech.
15: 1266-70. These analytical methods may also be used to investigate the interaction between a receptor protein and peptides selected by phage display, which may suggest further modification of the peptides to increase binding affinity.
Other methods compete with phage display in peptide research. A peptide library can be fused to the carboxyl terminus of the lac repressor and expressed in
E. coli
. Another
E. coli
-based method allows display on the cell's outer membrane by fusion with a peptidoglycan-associated lipoprotein (PAL). Hereinafter, these and related methods are collectively referred to as “
E. coli
display.” In another method, translation of random RNA is halted prior to ribosome release, resulting in a library of polypeptides with their associated RNA still attached. Hereinafter, this and related methods are collectively referred to as “ribosome display.” Other methods employ peptides linked to RNA; for example, PROfusion technology, Phylos, Inc. See, for example, Roberts & Szostak (1997),
Proc. Natl. Acad. Sci. USA,
94: 12297-303. Hereinafter, this and related methods are collectively referred to as “RNA-peptide screening.” Chemically derived peptide libraries have been developed in which peptides are immobilized on stable, non-biological materials, such as polyethylene rods or solvent-permeable resins. Another chemically derived peptide library uses photolithography to scan peptides immobilized on glass slides. Hereinafter, these and related methods are collectively referred to as “chemical-peptide screening.” Chemical-peptide screening may be advantageous in that it allows use of D-amino acids and other unnatural analogues, as well as non-peptide elements. Both biological and chemical methods are reviewed in Wells & Lowman (1992),
Curr. Opin. Biotechnol.
3: 355-62. Conceptually, one may discover peptide mimetics of any protein using phage display, RNA-peptide screening, and the other methods mentioned above.
SUMMARY OF THE INVENTION
The present invention concerns therapeutic agents that have activity similar to Apo-AI amphipathic helix peptide but with better pharmaceutical characteristics (e.g., half-life). In accordance with the present invention, such compounds comprise:
a) a Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domain, preferably having the sequence of Apo-AI amphipathic helix peptide, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques mentioned above; and
b) a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred;
wherein the vehicle is covalently attached to the Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domain. The vehicle and the Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domain may be linked through the N- or C-terminus of the Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domain, as described further below. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain. Apo-AI amphipathic helix peptide-mimetic domains can be generated by phage display, RNA-peptide screening and the other techniques mentioned herein.
Further in accordance with the present invention is a process for making therapeutic agents having Apo-AI amphipathic helix peptide activity, which comprises:
a. selecting at least one peptide having Apo-AI amphipathic helix peptide activity; and
b. covalently linking said peptide to a vehicle.
The preferred vehicle is an Fc domain. Step (a) is preferably carried out by selection SEQ ID NO: 7 or a sequence randomized therefrom from phage display, RNA-peptide screening, or the other techniques mentioned herein.
The compounds of this invention may be prepared by standard synthetic methods, recombinant DNA techniques, or any other methods of preparing peptides and fusion proteins. Compounds of this invention that encompass non-peptide portions may be synthesized by standard organic chemistry reactions, in addition to standard peptide chemistry reactions when applicable.
The primary use contemplated for the compounds of this invention is as therapeutic or prophylactic agents. The vehicle-linked peptide may have activity comparable to—or even greater than—the natural ligand mimicked by the peptide.
The compounds of this invention may be used for therapeutic or prophylactic purposes by formulating them with appropriate pharmaceutical carrier materials and administering an effective amount to a patient, such as a human (or other mammal) in need thereof. Other related aspects are also included in the instant invention.
Numerous additional aspects and advantages of the present invention will become apparent upon consideration of the figures and detailed descr

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Apo-AI/AII peptide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Apo-AI/AII peptide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apo-AI/AII peptide derivatives will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3308971

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.